Plasma brain natriuretic peptide levels in normotensive type 2 diabetic patients without cardiac disease.

Isotani, Haruhiko; Kameoka, Keiichi; Sasaki, I; Hida, Hirotake; Kakutani, Shinichi; Tasaki, Takashi

doi:10.2337/diacare.23.6.859

Cited by 12 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 (C), even the level of HbA1c could not change the plasma BNP level, although there were no differences in other parameters, including age, duration of diabetes, BMI, or the levels of blood pressure or lipid (data not shown). Differently from our finding, Isotani et al have reported that there was a negative correlation between the levels of plasma BNP and HbA1c [14]. With regard to the reason, they speculated about the presence of plasma osmotic diuretics by hyperglycemia, but it is plausible to assume that 7.6% of HbA1c was not high enough to induce diabetic polyuria.…”

Section: Discussioncontrasting

confidence: 56%

“…These reports appear to suggest that BNP might be related to the presence of diabetic complications. On the other hand, contrary to these reports, no other trials have demonstrated the existence of any relationship between the plasma BNP level and complications, such as albuminuria and reti-nopathy, in normotensive diabetic patients without cardiac diseases [14,15].…”

mentioning

confidence: 47%

See 1 more Smart Citation

Characterization of Plasma Brain Natriuretic Peptide Level in Patients with Type 2 Diabetes

et al. 2005

View full text Add to dashboard Cite

Abstract. This study investigates whether the plasma brain natriuretic peptide (BNP) level is increased by the clinical traits of diabetes, including its complications, and whether these levels are affected by the presence of other combined diseases such as hypertension, hyperlipidemia, and coronary heart disease (CHD) in patients with diabetes. In 223 patients with Type 2 diabetes, the mean value of plasma BNP reached 32.3 ± 4.1 pg/mL. The levels significantly increased with age, hypertension, and CHD but not with the duration of diabetes, HbA1c level, or hyperlipidemia. With regard to the type of therapy, the BNP levels were significantly lower in the combinations of both sulfonylurea and metformin and sulfonylurea and pioglitazone than those in insulin alone. In addition, the BNP levels in the group with diabetic complications, including retinopathy and nephropathy, and macroalbuminuria were significantly elevated in comparison with those without these complications and macroalbuminuria. Interestingly, however, no difference was observed between these groups after removal of the values in patients with CHD. These results have clarified that the plasma BNP levels in diabetic patients could increase only by the progression of macrovascular diseases, such as CHD, but not by the current diabetic control or diabetic microvascular complications.

show abstract

Section: Discussioncontrasting

confidence: 56%

mentioning

confidence: 47%

Characterization of Plasma Brain Natriuretic Peptide Level in Patients with Type 2 Diabetes

et al. 2005

View full text Add to dashboard Cite

show abstract

“…In previous epidemiological studies regarding the association BNP and renal function, plasma BNP ranged from 10.8 to 46.3 ng/dL [5][6][7][8][9]. The discrepancies among these studies may be explained, at least in part, by differences in sample size; the definition of renal function; characteristics such as age, sex, race, BMI, prevalence of coronary heart diseases, subclinical heart failure and hypertension; and other confounding factors.…”

Section: Discussionmentioning

confidence: 87%

“…On the other hand, in a Japanese study of 100 normotensive patients with type 2 diabetes mellitus, BNP level was not positively associated with microalbuminuria [8]. In another Japanese study of 100 normotensive patients with type 2 diabetes mellitus, BNP level was not associated with proteinuria [9]. In a Japanese cohort study of 97 patients with type 2 diabetes mellitus and microalbuminuria, low BNP at baseline was a predictor for remission of diabetic nephropathy [13].…”

Section: Discussionmentioning

confidence: 99%

“…In a Japanese study of diabetic patients without coronary heart diseases, BNP level was positively associated with macroalbuminuria but not microalbuminuria [7]. On the other hand, in two Japanese studies of normotensive patients with type 2 diabetes mellitus, BNP level was not associated with either microalbuminuria [8] or proteinuria [9]. The association between BNP The definition of diabetic retinopathy was based on the Fukuda standard [10].…”

mentioning

confidence: 99%

See 1 more Smart Citation

B-type natriuretic peptide and renal function in Japanese patients with type 2 diabetes mellitus: The Dogo Study

et al. 2017

View full text Add to dashboard Cite

THE LEADING CAUSE OF THE DEATH among patients with renal dysfunction is cardiovascular diseases [1], and the importance of the interaction between the heart and kidneys is widely note [2]. Plasma B-type natriuretic peptide (BNP) releases from the ventricles in response to hemodynamic stress, and BNP is one of the predictive markers for cardiovascular events [3,4].Among patients with type 2 diabetes mellitus, sev- Abstract. Among patients with type 2 diabetes mellitus, the association between B-type natriuretic peptide (BNP) and renal function remains controversial. We therefore investigated this issue among Japanese patients with type 2 diabetes mellitus. This study included 687 Japanese patients with type 2 diabetes mellitus. BNP levels were divided at quartile points on the basis of the distribution. We used four outcomes regarding the renal function: 1) chronic kidney disease (CKD): estimated glomerular filtration rate (eGFR) < 60mL/min/1.72m 2 , 2) advanced CKD: eGFR < 30mL/min/1.72m 2 , 3) microalbuminuria: urinary albumin creatinine ratio (UACR) ≥ 30 mg/g creatinine, and 4) macroalbuminuria: UACR ≥ 300 mg/g creatinine. The prevalence values of CKD, advanced CKD, microalbuminuria, and macroalbuminuria were 27.4, 2.5%, 31.4%, and 9.3%, respectively. Highest BNP (≥ 39.2 ng/mL) was independently positively associated with microalbuminuria and macroalbuminuria (adjusted ORs, 2.61 [95% CI: 1.53-4.49] and 3.45 [95% CI: 1.46-8.72], respectively). High BNP was not associated with advanced CKD or CKD. There was a statistically significant positive exposure-response relationships between the BNP level and advanced CKD, microalbuminuria, and macroalbuminuria (p for trend = 0.047, 0.001, and 0.003, respectively). BNP level may be independently positively associated with advanced CKD, microalbuminuria, and macroalbuminuria but not CKD in Japanese patients with type 2 diabetes mellitus.

show abstract

Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes

et al. 2007

View full text Add to dashboard Cite

We assessed the effect of the addition of pioglitazone on metabolic control and heart function of patients with type 2 diabetes already receiving sulfonylurea plus metformin. Forty-four patients were given 30 mg of pioglitazone for 3 months. Physical examination, laboratory tests including N-terminal pro-brain natriuretic peptide (NT-proBNP), and echocardiography, were performed at baseline and at study completion. Target HbA(1c) levels were achieved by 44.2% of the patients. Pioglitazone ameliorated lipid profile and lowered liver enzymes and C-reactive protein. Significant increases in NT-proBNP by 39% (P < 0.005) were noticed, but echocardiographic parameters were not altered, even in high-risk subgroups (patients older than 60 years, with diabetes for more than 10 years, with hypertension, with elevated baseline NT-proBNP levels, with left ventricular hypertrophy). In patients with a greater than 60% increase in NT-proBNP levels, a significant increase in left ventricular ejection fraction (P < 0.05) and in fractional shortening (P < 0.05) was found. None of the patients developed edema or signs or symptoms of heart failure. Triple oral combination antidiabetic treatment is an effective therapeutic strategy and weight gain does not abrogate its beneficial actions. Pioglitazone does not affect heart function and even though it increases NT-proBNP, this appears to represent a reaction to volume overload.

show abstract

Plasma brain natriuretic peptide levels in normotensive type 2 diabetic patients without cardiac disease.

Abstract: Sane , Saito H: Endogenous glucose production and glucose effectiveness in type 2 diabetic subjects derived from stablelabeled minimal model approach.

Cited by 12 publications

References 0 publications

Characterization of Plasma Brain Natriuretic Peptide Level in Patients with Type 2 Diabetes

Characterization of Plasma Brain Natriuretic Peptide Level in Patients with Type 2 Diabetes

B-type natriuretic peptide and renal function in Japanese patients with type 2 diabetes mellitus: The Dogo Study

Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes

Contact Info

Product

Resources

About